Published on
March 11, 2015
- 00:18 GMT
KEYTRUDA® (pembrolizumab) is First Medicine to be Made Available to Patients Through U.K. Early Access to Medicines Scheme (EAMS) ...
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the company’s anti-PD-1 therapy, pembrolizumab, which is marketed in the U.S. under the name KEYTRUDA®, is the first treatment to …
Distribution channels:
Companies
